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Background: Infectious diseases are major public health problem. It is increasingly affecting more than 50 million
people worldwide. Targeting shikimate pathway could be efficiently used for the development of broad spectrum
antimicrobial compound against variety of infectious diseases. Chorismate synthase is an enzyme in shikimate
pathway that catalyzes Phosphoenol pyruvate to chorismate in most of the prokaryotic bacteria. This step is crucial
for its growth, since Chorismate acts as a precursor molecule for the synthesis of aromatic amino acids. Hence, we
present a comprehensive database of Chorismate Synthase Database (CSDB) which is a manually curated
database. It provides information on the sequence, structure and biological activity of chorismate synthase from
shikimate pathway of pathogenic bacteria. Design of suitable inhibitors for this enzyme, hence could be a
probable solution to destroy its proteomic machinery and thereby inhibit the bacterial growth.
Description: The aim of this study was to characterise chorismate synthase enzyme belonging to pathogenic
bacteria to analysis the functional and structural characterization of chorismate synthase is very important for both
structure-based and ligand based drug design.
Conclusions: The broad range of data easy to use user interface makes csdb.in a useful database for researchers in
designing drugs.
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Biomolecules databases, in general contain gene function,
structure and localization of cell and chromosome. This
also includes clinical effects of mutations, sequence and
structural properties of proteins, domains, motifs and their
functional roles in a protein and pathway information [1].
Targeting the seven enzymes of shikimate pathway could
be an effective target for the development of antimicrobial
and herbicidal compounds as it is a crucial pathway for
synthesis of aromatic amino acid in bacteria and plants but
not in mammals [2-7]. Chorismate synthase (CS) catalyzes
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reproduction in any medium, provided the or(EPSP) to chorismate, is the final step of shikimate path-
way [3,8]. It is also an essential precursor for the synthe-
sis of p-aminobenzoic acid and folate [9].
Chorismate synthase also plays a remarkable role
in the biosynthesis of nucleotides. The reaction of
chorismate synthase is unique in nature, involves a 1, 4
elimination of phosphate and loss of proton of the C-6
hydrogen. The formation of two out of three necessary
double bonds to build an aromatic amino acid is aided
by CS and activity of this enzyme requires reduced
FMN molecule which is not consumed during the reac-
tion. In the elimination reaction the most accepted
mechanism suggests a direct role of reduced FMN that
transfers the electron to phosphate and the substrate
donates an electron for the regeneration of FMN.
Furthermore, the monofunctional form of chorismate
synthase is found in plants and bacteria whereas in bi-
functional it occurs in fungi [3].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 List of chorismate synthase inhibitors
Sl no Pathogen name Inhibitors name IC50 nM Ki nM






















(2E)-6,7-dihydroxy-2-[(2-hydroxy-4-pentoxyphenyl)methylidene]-1-benzofuran-3- one 220.0 n/a
(2E)-2-[(4-hexoxy-2-hydroxyphenyl)methylidene]-6, 7-dihydroxy-1-benzofuran-3-one 320.0 n/a
(2E)-2-[(4-butoxy-2-hydroxyphenyl)methylidene]-6, 7-dihydroxy-1-benzofuran-3-one 450.0 n/a
(2E)-6,7-dihydroxy-2-[(2-hydroxy-4-propoxyphenyl)methylidene]-1-benzofuran-3- one 510.0 n/a





(2E)-6,7-dihydroxy-2-[(2-hydroxy-3-methoxyphenyl)methylidene]-1-benzofuran-3- one 800.0 n/a
(2E)-6,7-dihydroxy-2-[[2-hydroxy-4-(4-hydroxybutoxy)phenyl]methylidene]-1- benzofuran-3-one 860.0 n/a
(2E)-6,7-dihydroxy-2-[(2-hydroxy-4-propan-2-yloxyphenyl)methylidene]-1- benzofuran-3-one 1000.0 n/a
(2E)-6,7-dihydroxy-2-[(2-hydroxy-4-phenylmethoxyphenyl)methylidene]-1- benzofuran-3-one 1000.0 n/a
4-[4-[(E)-(6,7-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]-3-hydroxyphenoxy] butanenitrile 1100.0 n/a
4-[4-[(E)-(6,7-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]-3-hydroxyphenoxy] butanoic acid 1100.0 n/a
(2E)-2-[(4-butoxyphenyl)methylidene]-6,7-dihydroxy-1-benzofuran-3-one 1500.0 n/a
(2E)-6,7-dihydroxy-2-[[2-hydroxy-4-(6-hydroxyhexoxy)phenyl]methylidene]-1- benzofuran-3-one 1600.0 n/a
(2E)-6,7-dihydroxy-2-[(2-hydroxy-4-methoxyphenyl)methylidene]-1-benzofuran-3- one 1700.0 n/a
2-[2-[(E)-(6,7-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]phenoxy]acetic acid 1800.0 n/a
(2E)-6,7-dihydroxy-2-[(2-nitrophenyl)methylidene]-1-benzofuran-3-one 2000.0 n/a
(2E)-6,7-dihydroxy-2-[[2-hydroxy-4-(3-hydroxypropoxy)phenyl]methylidene]-1- benzofuran-3-one 2500.0 n/a












(2E)-6,7-dihydroxy-2-[[4-(trifluoromethyl)phenyl]methylidene]-1-benzofuran-3- one 7000.0 n/a
(2E)-2-[[4-(diethylamino)phenyl]methylidene]-6,7-dihydroxy-1-benzofuran-3-one 8500.0 n/a
ethyl 2-[4-[(E)-(6, 7-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]-3-hydroxyphenoxy] acetate 10300.0 n/a
2-[(E)-(6,7-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]benzoic acid 10700.0 n/a
(2E)-6,7-dihydroxy-2-[(4-methoxyphenyl)methylidene]-1-benzofuran-3-one 14300.0 n/a
(2E)-6,7-dihydroxy-2-[(4-hydroxyphenyl)methylidene]-1-benzofuran-3-one 15000.0 n/a
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Table 1 List of chorismate synthase inhibitors (Continued)
(2E)-6,7-dihydroxy-2-[[2-(trifluoromethyl)phenyl]methylidene]-1-benzofuran-3- one 17300.0 n/a
4-[(E)-(6,7-dihydroxy-3-oxo-1-benzofuran-2-ylidene)methyl]benzoic acid 24000.0 n/a
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achieved largely by studying mutants lacking the individ-
ual enzyme activities. Shikimate pathway is essential in
bacteria since enzymatic mutations in this pathway com-
pletely inhibit the growth in culture unless aromatic sup-
plements are provided [10]. Studies of Barea and Giles
showed that shikimate pathway in fungi play an essential
role in synthesis of aromatic amino acid [11]. The gen-
omic studies confirmed that this pathway could be effi-
ciently used for the development of broad spectrum
antimicrobial compound against variety of infectious dis-
eases [10]. Earlier reports have shown that inhibition of
one of the enzyme of shikimate pathway could efficiently
treat the opportunistic pathogens such as PneumocystisFigure 1 Structure of Chorismate synthase database.carinii, Mycobacterium tuberculosis, Cryptosporidium
parvum and Toxoplasma gondii, which may simultan-
eously infect AIDS and other immune compromised
patients [12].
A promising drug target for bacterial pathogenic
diseases could be developed by blocking any enzymes
of this pathway. Designing inhibitors for this reaction
would greatly facilitate researchers to block multiple path-
ways essential for the survival of micro organism. The
Chorismate Synthase Database provides data incorpor-
ating all the parameters required for the inhibition of
chorismate synthase in 42 pathogenic bacterial species
which is a potential drug target for blocking the
shikimate pathway. A list of 48 inhibitors reported in
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in Table 1.
Construction and content
Data sources and curation
The starting point for data curation in Chorismate
Synthase Database is a manual curation of all publicly
available sequence, structure and functional information
for pathogens from UniProtKB [13,14]. Other database
identifiers (e.g. NCBI taxonomy codes, Gene Ontology
classifications, InterPro and Pfam accessions, super
family, SCOP, prosite, KEGG, Pubchem Substance,
etc.,) were also imported apart from the literature refer-
ences, annotations of sequence and structure features.
CSDB taxonomy is derived from the NCBI taxonomy
database.
The data in CSDB is organized into 7 fields (Figure 1)
such as protein resources, gene annotations, features,
gene and nucleotide sequence, pathways, molecularFigure 2 Schematic workflow for homology modeling.target, taxonomical ID and literature references. The
classification of pathogenic bacteria used in CSDB is
similar to that of the already available pathogenic bacteria
listed in “Classification of Pathogenic Bacteria” available at
the weblink (http://www.buzzle.com/articles/pathogenic-
bacteria-list.html). Links are provided to access further
information on the Pathogenic Bacteria, if present in
external databases like Swiss-Prot, NCBI Taxonomy
Browser, EMBL-EBI, Sanger institute, chemical database,
PDB and Pubmed reference etc.,
An extensive literature survey was carried out using
PUBMED and MEDLINE to extract information about
human diseases caused by various bacterial pathogens.
Critical features related to chorismate synthase for each
bacterial strain such as gene sequence, gene id, protein
sequence in fasta format, domain and motif information
were retrieved from domain and motif databases. The
structure related information were retrieved from PDB,
CATH, and SCOP, kinetic data from literature, pathway
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mation were retrieved from GO database. A database
was constructed using these information by integrating
them appropriately in a flat file format.
The features of this database can be categorized in to
three broad areas:
1. Query interface: The query interface is a collection
of all the pathogenic bacteria with their strain
information available in literature and relates to the
disease it causes to humans.
2. Feature enrichment: Feature enrichment category is
sequence annotation from well curated databases,
multiple sequence alignment in chorismate synthase of
all strains and 3D structure determination using
Modeller v.9.10 and its validation using GNR plot.
3. External references/links: This category includes
pathogenic organism database, Genome databases,
Database of protein-protein interactions, Systems
Biology pathways, Drug bank and Structure
prediction servers.
The molecular modeling in this work was performed by
the MODELLER version 9.10. The MODELLER program
was completely automated to calculate comparative
models for a large number of protein sequences, by using
many different template structures and sequence-
structure alignments [15-17]. Sequence-structure matches
are established by aligning SALIGN [18,19]. SequenceFigure 3 Schematic draw showing the Interaction of web client interfprofile of the target sequence against each of the template
sequences extracted from PDB [14] (Figure 2).Database architecture
CSDB is built on Apache HTTP Server 2.2.11 with MySQL
Server 5.1.36 as the back-end and PHP 5.3.0, HTML
and JavaScript, CSS as the front-end. Apache, MySQL and
PHP technology were preferred as they are open-source
software’s and platform independent. Besides these advan-
tages, MySQL is the most popular open source SQL
(Structured Query Language) database over the internet.
MySQL (Figure 3) is a relational database management
system that works much faster which also supports multi-
user and multi-threading. It can work both on Windows
and Linux. It comes with Triggers, Cursors and stored
procedures to improve the productivity of developers.Utility and discussion
Data access
Data stored in CSDB can be accessed in the following
ways: (i) Search options in CSDB: CSDB can be queried to
obtain pathogen information. In order to facilitate this,
simple search options or manual browse option have been
provided in the ‘Search’ section.
Select pathogenic bacteria: the user can select patho-
genic bacteria to obtain related information on bacteria.
(Figure 4) illustrates the result of organism-based search).ace.
Figure 4 Chorismate synthase database search section. (A) Organism based selection. (B) The list of proteins found in a selected organism.
(C) The list of selected protein with their major features.
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External database links are provided in the web portal by
using hyperlinks to other useful bioinformatics resources
such as genome database, protein-protein interactions data-
bases, system biology pathways, pathogenic organism data-
bases, microarray databases, structure prediction server and
GENE CARDS.
Feedback
Users can submit their suggestions/comments/queries
using this feature.
Help
A detailed description on the use of the various features
incorporated in CSDB is provided in this section for the
benefit of users.
Future work
The resource will be updated constantly with further
enhanced features. We also intend to add some
bioinformatics tools on structural and sequence analysis
in future versions. We would also like to extend this
database for other pathogens.
Conclusions
The CSDB provides manually curated information on
analysis of chorismate synthase in 42 pathogenic bacter-
ial species. This database provides information useful for
designing a drug in both ligand as well as structure
based methods. For structure based drug design, infor-
mation on the protein’s motif and Interpro’s/PFAM
domain categorization are been added and 48 inhibitors
with IC50/Ki values are made available for designing
inhibitors using Ligand based drug design strategies
[Table 1]. In addition to this, this database also contains
information about the protein’s superfamily, SCOP IDs,
GO IDs, active site residues pathway information using
KEGG, taxonomy, and structural models using modeler
9.10. This facilitates their usage in drug design for
researchers. This database is freely available at the
website http://www.csdb.in.Availability and requirements
CSDB is freely available at http://www.csdb.in.
Download
CSDB database contents can be downloaded easily from
the ‘Download Database’ section. Users can obtain the
entire collection of ID’s at SQL format with a single
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